https://www.novumpr.nl/2017/10/04/gilead-presents-results-from-phase-3-study-evaluating-patients-who-switched-to-investigational-fixed-dose-combination-of-bictegravir-emtricitabine-and-tenofovir-alafenamide-from-boosted-protease-inhi/?utm_source=rss&utm_medium=rss&utm_campaign=gilead-presents-results-from-phase-3-study-evaluating-patients-who-switched-to-investigational-fixed-dose-combination-of-bictegravir-emtricitabine-and-tenofovir-alafenamide-from-boosted-protease-inhi NovumPR press releases Wed, 04 Oct 2017 12:48:37 +0000 hourly 1 https://wordpress.org/?v=6.8.3